CMAS

Across TCGA cell cohorts, CMAS mutation is significantly associated with the drug of many other genes, with 6 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible CMAS-associated genes across cancer lineages are Niraparib, KRAS (G12C) Inhibitor-12, and GSK429286A. Each is linked with CMAS in more than 1 cancer types. Because this analysis shows association rather than direction, both CMAS-to-partner and partner-to-CMAS results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Niraparib grouped by CMAS-low versus CMAS-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (CMAS→partner) and Y-score (partner→CMAS) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Niraparib →	+0.358	+2.646	.045	.047	3	1
LARGE_INTESTINE	KRAS (G12C) Inhibitor-12 →	+0.562	+2.646	.024	.047	3	1
LARGE_INTESTINE	GSK429286A →	+0.315	+2.652	.044	.045	3	1
LARGE_INTESTINE	CDK9_5038 →	+0.621	+2.906	.024	.033	1	1
LARGE_INTESTINE	LY2109761 →	+0.341	+2.646	.042	.047	1	1
LARGE_INTESTINE	CX-5461 →	+0.731	+2.652	.012	.045	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 6 associations by consensus.

Niraparib by CMAS expression — LARGE_INTESTINE

Explore this box plot interactively →